Search Results - "Shune, Leyla"

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019 by Balmaceda, Nicole, Aziz, Muhammad, Chandrasekar, Viveksandeep Thoguluva, McClune, Brian, Kambhampati, Suman, Shune, Leyla, Abdallah, Al-Ola, Anwer, Faiz, Majeed, Aneela, Qazilbash, Muzaffar, Ganguly, Siddhartha, McGuirk, Joseph, Mohyuddin, Ghulam Rehman

“…Abstract Background Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments…”
Get full text

Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United States by Emole, Josephine, Lawal, Odunayo, Lupak, Oleksandra, Dias, Ajoy, Shune, Leyla, Yusuf, Korede

“…Background It is not clear if all Americans have benefitted equally from the availability of chimeric antigen receptor T‐cell (CART) therapy. We aimed to…”
Get full text

Hospitalization at the end of life in patients with multiple myeloma by Abbasi, Saqib, Roller, John, Abdallah, Al-Ola, Shune, Leyla, McClune, Brian, Sborov, Douglas, Mohyuddin, Ghulam Rehman

“…Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where…”
Get full text

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment by Sidana, Surbhi, Peres, Lauren C, Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher, Khouri, Jack, Dima, Danai, Atrash, Shebli, Voorhees, Peter, Simmons, Gary, Sborov, Douglas W, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Miklos, David, Wagner, Charlotte, Kocoglu, Mehmet H, Kaur, Gurbakhash, Davis, James A, Midha, Shonali, Janakiram, Murali, Freeman, Ciara, Alsina, Melissa, Locke, Frederick, Gonzalez, Rebecca, Lin, Yi, McGuirk, Joseph, Afrough, Aimaz, Shune, Leyla, Patel, Krina K, Hansen, Doris K

“…We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes…”
Get full text

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience by Hashmi, Hamza, Hansen, Doris K, Peres, Lauren C, Puglianini, Omar Castaneda, Freeman, Ciara, De Avila, Gabriel, Sidana, Surbhi, Shune, Leyla, Sborov, Douglas W, Davis, James, Wagner, Charlotte, Kocoglu, Mehmet H, Atrash, Shebli, Voorhees, Peter, Simmons, Gary, Ferreri, Christopher, Kalariya, Nilesh, Anderson, Jr, Larry D, Afrough, Aimaz, Dima, Danai, Khouri, Jack, McGuirk, Joseph, Locke, Fred, Baz, Rachid, Patel, Krina K, Alsina, Melissa

“…While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse…”
Get full text

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM) by Pennipede, Dante, Mohyuddin, Ghulam Rehman, Hawkins, Ryan, Ganguly, Siddhartha, Shune, Leyla, Ahmed, Nausheen, Mohan, Meera, Cui, Wei, Mahmoudjafari, Zahra, McGuirk, Joseph, Atrash, Shebli, Abdallah, Al‐Ola

“…Background Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple‐class relapsed/refractory MM (RRMM)…”
Get full text

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy by Ahmed, Nausheen, Wesson, William, Mushtaq, Muhammad Umair, Bansal, Rajat, AbdelHakim, Haitham, Bromert, Sarah, Appenfeller, Allison, Ghazal, Batool Abu, Singh, Anurag, Abhyankar, Sunil, Ganguly, Siddhartha, McGuirk, Joseph, Abdallah, Al-Ola, Shune, Leyla

“…Background The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after…”
Get full text

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN by Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya, Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Richardson, Paul G., Voorhees, Peter

Get full text

Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity by Lutfi, Forat, Abdallah, Al-Ola, Nashatizadeh, Muhammad, Ahmed, Nausheen, Nelson, Maggie, Hamideh, Janna, Mahmoudjafari, Zahra, Shune, Leyla

“…T-cell re-directing bispecific antibodies targeting B-cell maturation antigens have recently entered real-world use in relapsed/refractory multiple myeloma…”
Get full text

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel by Zanwar, Saurabh, Sidana, Surbhi, Shune, Leyla, Puglianini, Omar Castaneda, Pasvolsky, Oren, Gonzalez, Rebecca, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Davis, James A, Herr, Megan, Hashmi, Hamza, Forsberg, Peter, Sborov, Douglas, Anderson, Jr, Larry D, McGuirk, Joseph P, Wagner, Charlotte, Lieberman-Cribbin, Alex, Rossi, Adriana, Freeman, Ciara L, Locke, Frederick L, Richard, Shambavi, Khouri, Jack, Lin, Yi, Patel, Krina K, Kumar, Shaji K, Hansen, Doris K

“…Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM)…”
Get full text

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy by Dima, Danai, Abdallah, Al-Ola, Davis, James A., Awada, Hussein, Goel, Utkarsh, Rashid, Aliya, DeJarnette, Shaun, Anwer, Faiz, Shune, Leyla, Raza, Shahzad, Mahmoudjafari, Zahra, Williams, Louis, Faiman, Beth, McGuirk, Joseph P., Sauter, Craig S., Ahmed, Nausheen, Khouri, Jack, Hashmi, Hamza

“…The presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we…”
Get full text

A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease by Soder, Rupal P, Dawn, Buddhadeb, Weiss, Mark L, Dunavin, Neil, Weir, Scott, Mitchell, James, Li, Meizhang, Shune, Leyla, Singh, Anurag K, Ganguly, Siddhartha, Morrison, Marc, Abdelhakim, Haitham, Godwin, Andrew K, Abhyankar, Sunil, McGuirk, Joseph

“…Because of their well-described immunosuppressive properties, allogeneic adult human mesenchymal stromal cells (MSC) derived from bone marrow have demonstrated…”
Get more information

Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience by Kalariya, Nilesh M., Hildebrandt, Michelle A. T., Hansen, Doris K., Sidana, Surbhi, Khouri, Jack, Ferreri, Christopher J., Doyle, William N., Castaneda-Puglianini, Omar, Freeman, Ciara L., Hovanky, Vanna, Hosoya, Hitomi, Shune, Leyla O., Patel, Krina K.

“…•The safety and efficacy benefits of ide-cel were proportionate in young and older patients despite frailty and geriatric characteristics.•Treatment with…”
Get full text

Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium by Afrough, Aimaz, Hashmi, Hamza, Hansen, Doris K., Sidana, Surbhi, Ahn, Chul, Peres, Lauren C., Dima, Danai, Freeman, Ciara L., Puglianini, Omar Castaneda, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter M., Shune, Leyla, McGuirk, Joseph P., Simmons, Gary, Sborov, Douglas W., Davis, James A., Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Gaballa, Mahmoud R., Goldsmith, Scott, Nadeem, Omar, Midha, Shonali, Wagner, Charlotte B., Locke, Frederick L., Patel, Krina K., Khouri, Jack, Anderson, Larry D., Lin, Yi

Get full text

Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition by Masood, Ashiq, Christ, Trevor, Asif, Samia, Rajakumar, Priya, Gustafson, Beth A., Shune, Leyla O., Salahudeen, Ameen, Nedvad, Drew, Nanua, Suparna, Paner, Agne, Kuzel, Timothy M., Levy, Mia, Subramanian, Janakiraman, Raza, Shahzad

“…Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and…”
Get full text

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma by Gil, Kellen, Abbasi, Saqib, Mehta, Kathan, McClune, Brian, Sborov, Douglas, Ahmed, Nausheen, Abdallah, Al-Ola, Ganguly, Siddhartha, McGuirk, Joseph, Shune, Leyla, Mohyuddin, Ghulam Rehman

Get full text

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease by Abdallah, Al‐Ola, Mohyuddin, Ghulam Rehman, Ahmed, Nausheen, Mohan, Meera, Cui, Wei, Shune, Leyla, Mahmoudjafari, Zahra, McGuirk, Joseph, Ganguly, Siddhartha, Atrash, Shebli

“…Extramedullary disease (EMD) is an aggressive form of multiple myeloma (MM). Confirming the presence of plasma cells outside the bone marrow makes the…”
Get full text

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy by Ferreri, Christopher J., Hildebrandt, Michelle A. T., Hashmi, Hamza, Shune, Leyla O., McGuirk, Joseph P., Sborov, Douglas W., Wagner, Charlotte B., Kocoglu, M. Hakan, Rapoport, Aaron, Atrash, Shebli, Voorhees, Peter M., Khouri, Jack, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Anderson, Larry D., Simmons, Gary, Davis, James A., Kalariya, Nilesh, Peres, Lauren C., Lin, Yi, Janakiram, Murali, Nadeem, Omar, Alsina, Melissa, Locke, Frederick L., Sidana, Surbhi, Hansen, Doris K., Patel, Krina K., Castaneda Puglianini, Omar Alexis

“…Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing…”
Get full text

De Novo Acute Myeloid Leukemia with Combined CBFB-MYH11 and BCR-ABL1 Gene Rearrangements: A Case Report and Review of Literature by Golem, Shivani, Gonzales, Patrick R., El Atrouni, Wissam, Shune, Leyla, Jabr, Ra’ed, Sethapati, Venkata Rakesh, Cui, Wei

“…Acute myeloid leukemia (AML) with inv(16)(p13.1q22) resulting in CBFB-MYH11 fusion is associated with a favorable prognosis. The presence of a KIT mutation…”
Get full text

Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies by Shah, Gunjan L, Shune, Leyla, Purtill, Duncan, Devlin, Sean, Lauer, Emily, Lubin, Marissa, Bhatt, Valkal, McElrath, Courtney, Kernan, Nancy A, Scaradavou, Andromachi, Giralt, Sergio, Perales, Miguel A, Ponce, Doris M, Young, James W, Shah, Monica, Papanicolaou, Genovefa, Barker, Juliet N

“…Abstract Because cord blood (CB) lacks memory T and B cells and recent decreases in herd immunity to vaccine-preventable diseases in many developed countries…”
Get full text